Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with increased risk in patients with metabolic syndrome. There are no FDA-approved treatments, but FXR agonists have shown promising results in clinical studies for NAFLD management. In addition to FXR, fibroblast grow...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreau, Francois, Brunao, Bruna Brasil, Liu, Xiang-Yu, Tremblay, Frederic, Fitzgerald, Kevin, Avila-Pacheco, Julian, Clish, Clary, Kahn, Ronald C., Softic, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871743/
https://www.ncbi.nlm.nih.gov/pubmed/36586437
http://dx.doi.org/10.1016/j.jlr.2022.100324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871743/
https://www.ncbi.nlm.nih.gov/pubmed/36586437
http://dx.doi.org/10.1016/j.jlr.2022.100324

Ejemplares similares